/ ASCO Briefing Room 2025
The Breast Cancer Briefing Room - ASCO 2025
Outcomes4Me in partnership with CURE brings you access to exclusive, hand-selected coverage of ASCO abstracts, sessions and key data specific to Breast Cancer, curated with scientific excellence and a patient-first perspective.
Articles
From targeted therapies to managing side effects, this year’s American Society of Clinical Oncology (ASCO)...
Safety outcomes with first-line treatment of Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) plus Perjeta (pertuzumab) is comparable...
Enhertu (fam-trastuzumab deruxtecan-nxki or T-DXd) has shown promising results in slowing down or stopping the...
The American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30...
A recent study is aiming to understand and classify the HER2 protein levels in breast...
One of the most important first steps after receiving a breast cancer diagnosis is understanding...
